AtaiBeckley's Lead Depression Drug Advances to Phase 3 After FDA Nod
ATAI has more than doubled off its 52-week low of $2.58.
Summary
Eli Lilly has agreed to acquire AtaiBeckley for an initial $2.8 billion, valuing the company at $6.75 per share plus contingent value rights. AtaiBeckley's lead asset, BPL-003, a synthetic 5-MeO-DMT intranasal treatment for treatment-resistant depression, has advanced to Phase 3 following Breakthrough Therapy Designation from the FDA. Phase 2b data showed rapid, durable symptom reduction after a roughly two-hour in-clinic visit, with effects lasting months. The Phase 3 initiation validates the pipeline and could strengthen the deal's strategic rationale. A second asset, VLS-01, is also in Phase 2b, broadening the neuroscience portfolio.
At the time of this announcement, ATAI was trading at $7.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.58 to $6.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.